Header Logo

Connection

HOWARD WEINER to Kaplan-Meier Estimate

Back to Details
This is a "connection" page, showing publications HOWARD WEINER has written about Kaplan-Meier Estimate.
HOWARD WEINER
Connection Strength
0.072
Kaplan-Meier Estimate
  1. An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy. Mult Scler. 2014 Sep; 20(10):1381-90.
    View in: PubMed
    Score: 0.021
  2. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012 Nov 24; 380(9856):1819-28.
    View in: PubMed
    Score: 0.019
  3. Bevacizumab in recurrent high-grade pediatric gliomas. Neuro Oncol. 2010 Sep; 12(9):985-90.
    View in: PubMed
    Score: 0.016
  4. Smoking and disease progression in multiple sclerosis. Arch Neurol. 2009 Jul; 66(7):858-64.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.